Last reviewed · How we verify
NCT01117935
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
NA trial testing intensity modulated external beam radiation therapy in Adenocarcinoma of the Prostate in 55 participants. Completed in 1 March 2019.
25 June 2015
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 55 |
| Start date | 30 May 2010 |
| Primary completion | 25 June 2015 |
| Estimated completion | 1 March 2019 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- intensity modulated external beam radiation therapy
Conditions studied
- Adenocarcinoma of the Prostate — all drugs for Adenocarcinoma of the Prostate →
- Stage I Prostate Cancer — all drugs for Stage I Prostate Cancer →
- Stage II Prostate Cancer — all drugs for Stage II Prostate Cancer →
- Stage III Prostate Cancer — all drugs for Stage III Prostate Cancer →
Sponsor
Virginia Commonwealth University
Who can join
18 and older, male only, with Adenocarcinoma of the Prostate or Stage I Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This clinical trial studies intensity-modulated external beam radiation therapy in treating patients with prostate cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial.
Ricco A, Mukhopadhyay N, Deng X, Holdford D, et al · · 2020 · cited 3× · PMID 32974208 · DOI 10.3389/fonc.2020.01686
Verify or expand the search:
- PubMed search for NCT01117935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adenocarcinoma of the Prostate
Currently open trials in the same condition.
- NCT04909294 — Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients · NA · active not recruiting
- NCT02176902 — Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer · NA · active not recruiting
- NCT02023463 — Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer · Phase 1 · active not recruiting
- NCT02296229 — Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer · NA · active not recruiting
- NCT01655836 — High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer · Phase 1 · active not recruiting
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01117935 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 28 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01117935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing